Careful candidate selection is the most decisive step for the safety and efficacy of phenol-croton oil peel. The process should integrate cutaneous and morphofunctional analysis—including skin thickness, dermal density, facial topography, phototype, and pigmentary risk—with scar history, previous surgeries, and anatomical features that may predispose to complications. Stratification by phototype, combined with assessment of melanocytic reactivity and a history of post-inflammatory hyperpigmentation, is essential to minimize dyschromia. Investigation of the scarring profile, with emphasis on keloids, hypertrophic scars, or post-surgical fibrosis, guides adapted management or contraindications. Systemic assessment should encompass cardiovascular, hepatic, renal, endocrine, infectious, and immunological comorbidities, as well as laboratory screening (ECG with QTc, liver/renal function, blood glucose, full blood count, serology). A thorough pharmacological review is mandatory, considering interactions that may increase the risk of arrhythmias, toxicity, or scarring delay. Nutrition, hydration, and functional support of the skin also influence wound healing and the predictability of outcomes. Psychological factors, realistic expectations, and the availability of a social support network are equally decisive for adherence to and coping with the postoperative period. Thus, assessment for phenol-croton oil peel is multidimensional, encompassing clinical, anatomical, laboratory, and psychosocial domains. This structured process ensures safe patient selection, maximizes benefits, and minimizes the risks associated with a highly complex procedure.